Literature DB >> 15877709

Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors.

A A Dahl1, A Ravindran, C Allgulander, S P Kutcher, C Austin, T Burt.   

Abstract

OBJECTIVE: The objective was to study the efficacy of sertraline on symptoms of psychic and somatic anxiety in patients suffering from moderate-to-severe generalized anxiety disorder (GAD).
METHOD: Out-patients with DSM-IV GAD were randomized to 12 weeks of double-blind treatment with placebo. The psychic and somatic anxiety factors of the Hamilton Anxiety Rating Scale (HAM-A) and the Quality of Life, Enjoyment, and Satisfaction Questionnaire were analyzed.
RESULTS: Treatment with sertraline resulted in significantly greater last observation carried forward (LOCF)-endpoint improvement than placebo on both the HAM-A psychic and somatic anxiety factors. At LOCF-endpoint, all items on the HAM-A psychic factor were more improved on sertraline than placebo, as were three of seven items on the somatic factor. Reduction of secondary depressive symptoms was more correlated with endpoint improvement in quality of life than either psychic- or somatic anxiety.
CONCLUSION: Sertraline treatment demonstrated efficacy for both the psychic and somatic anxiety symptoms of GAD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877709     DOI: 10.1111/j.1600-0447.2005.00529.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  8 in total

Review 1.  Generalised anxiety disorder.

Authors:  Christopher K Gale; Jane Millichamp
Journal:  BMJ Clin Evid       Date:  2011-10-27

Review 2.  Generalised anxiety disorder.

Authors:  Christopher K Gale; Jane Millichamp
Journal:  BMJ Clin Evid       Date:  2007-11-20

3.  The Effect of Sertraline on the Quality of Life for Children and Adolescents with Anxiety Disorder.

Authors:  Nursu Çakin Memik; Işık Karakaya; Özlem Yildiz; Şahika Şişmanlar; Çiğdem Çağlayan; Belma Ağaoğlu
Journal:  Noro Psikiyatr Ars       Date:  2014-03-01       Impact factor: 1.339

4.  Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.

Authors:  Jonathan R T Davidson; Douglas E Feltner; Ashish Dugar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

5.  Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms.

Authors:  James Russell; Joel Raskin; Curtis Wiltse; Daniel Walker; Olga Brawman-Mintzer
Journal:  Psychiatry (Edgmont)       Date:  2007-06

Review 6.  Redefining affective disorders: relevance for drug development.

Authors:  Steven D Targum; Mark H Pollack; Maurizio Fava
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

7.  Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population.

Authors:  Kaida Jiang; Lingjiang Li; Xueyi Wang; Maosheng Fang; Jianfei Shi; Qiuyun Cao; Jincai He; Jinan Wang; Weihao Tan; Cuili Hu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-17       Impact factor: 2.570

8.  Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity.

Authors:  Gavin J Lyndon; Rita Prieto; Dalia B Wajsbrot; Christer Allgulander; Borwin Bandelow
Journal:  Int Clin Psychopharmacol       Date:  2019-05       Impact factor: 1.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.